Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of Potential Biomarkers of EGFR Mutation in Pleural Effusion of Non-Small Cell Lung Cancer Patients Based on Metabolomics.

Clinical laboratory - 1 Jun 2024

Yu Jiangqing, Xu Hui, Feng Tanggui, Xie Tongshun, Shi Tiancheng

Abstract excerpt

BACKGROUND: Malignant pleural effusion (MPE) is a common complication of non-small cell lung cancer (NSCLC). Patients with NSCLC exhibit a high rate of epidermal growth factor receptor (EGFR) mutations. The detection of EGFR mutations is usually time-consuming and costly. This study aimed at identifying potential biomarkers of EGFR mutations in MPE of NSCLC patients by metabolomics. METHODS: In total, 58 MPE...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Metabolomics

Share to Pleural Effusion, Malignant

Share to Tandem Mass Spectrometry

Source

Identifiers

PMID: 38868885
DOI: 10.7754/Clin.Lab.2023.231105

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of Potential Biomarkers of EGFR Mutation in Pleural Effusion of Non-Small Cell Lung Cancer Patients Based on Metabolomics.PMID 38868885Read ↗

A pilot study identifying a potential plasma biomarker for determining EGFR mutations in exons 19 or 21 in lung cancer patients.Semantic proximity Read ↗

Targeted metabolomic profiling as a tool for diagnostics of patients with non- small-cell lung cancerSemantic proximity Read ↗

Circulating Tumor Cell and Metabolites as Novel Biomarkers for Early-stage Lung Cancer DiagnosisSemantic proximity Read ↗

Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites.Semantic proximity Read ↗

Advancing Non-Small-Cell Lung Cancer Management Through Multi-Omics Integration: Insights from Genomics, Metabolomics, and RadiomicsSemantic proximity Read ↗

Detection of EGFR mutation in supernatant, cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by high resolution melting analysis and sequencing.Semantic proximity Read ↗

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI.Semantic proximity Read ↗

Metabolomic profiling reveals distinct metabolic patterns and a potential circulating biomarker in pre-COPDSemantic proximity Read ↗

The complexity of EGFR exon 19 deletion and L858R mutant cells as assessed by proteomics, transcriptomics, and metabolomics.Semantic proximity Read ↗

Subtyping non-small cell lung cancer by histology-guided spatial metabolomics.Semantic proximity Read ↗

Differences in Pleural Fluid Amylase Levels in Patients with Malignant Pleural Effusion Based on Cancer Type, Histologic Type, and Epidermal Growth Factor Receptor Mutations.Semantic proximity Read ↗

Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.